DK1178780T3 - Multipartikelformige formuleringer til kontrolleret frigivelse af selektiv serotoningenoptagelseshæmmer - Google Patents

Multipartikelformige formuleringer til kontrolleret frigivelse af selektiv serotoningenoptagelseshæmmer

Info

Publication number
DK1178780T3
DK1178780T3 DK00925548T DK00925548T DK1178780T3 DK 1178780 T3 DK1178780 T3 DK 1178780T3 DK 00925548 T DK00925548 T DK 00925548T DK 00925548 T DK00925548 T DK 00925548T DK 1178780 T3 DK1178780 T3 DK 1178780T3
Authority
DK
Denmark
Prior art keywords
controlled release
serotonin reuptake
reuptake inhibitor
selective serotonin
ssri
Prior art date
Application number
DK00925548T
Other languages
English (en)
Inventor
Theresa Ann Jeary
Catherine Ann Morrissey
Paul Stark
Original Assignee
Elan Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IE19990406A external-priority patent/IE990406A1/en
Application filed by Elan Corp Plc filed Critical Elan Corp Plc
Application granted granted Critical
Publication of DK1178780T3 publication Critical patent/DK1178780T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00925548T 1999-05-20 2000-05-10 Multipartikelformige formuleringer til kontrolleret frigivelse af selektiv serotoningenoptagelseshæmmer DK1178780T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13502899P 1999-05-20 1999-05-20
IE19990406A IE990406A1 (en) 1999-05-20 1999-05-20 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
PCT/IE2000/000060 WO2000071099A1 (en) 1999-05-20 2000-05-10 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations

Publications (1)

Publication Number Publication Date
DK1178780T3 true DK1178780T3 (da) 2007-11-12

Family

ID=26320248

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00925548T DK1178780T3 (da) 1999-05-20 2000-05-10 Multipartikelformige formuleringer til kontrolleret frigivelse af selektiv serotoningenoptagelseshæmmer

Country Status (16)

Country Link
EP (2) EP1178780B1 (da)
JP (1) JP2003500348A (da)
AT (1) ATE367153T1 (da)
AU (1) AU782059B2 (da)
CA (2) CA2698347A1 (da)
CY (1) CY1107750T1 (da)
CZ (1) CZ302388B6 (da)
DE (1) DE60035579T2 (da)
DK (1) DK1178780T3 (da)
DZ (1) DZ3256A1 (da)
ES (1) ES2290027T3 (da)
HU (1) HU229569B1 (da)
PT (1) PT1178780E (da)
RU (1) RU2275191C2 (da)
SK (1) SK286865B6 (da)
WO (1) WO2000071099A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
BR0100334A (pt) * 2001-01-17 2002-09-24 Diffucap Chemobras Quimica E F Processo para a preparação de composições de liberação programada contendo venlafaxina e o produto resultante
PT1443917E (pt) * 2001-11-07 2006-06-30 Synthon Bv Comprimidos de tamsulosina
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
EP1502587B1 (en) 2003-07-30 2006-08-23 Pharmathen S.A. Sustained release formulation for Venlafaxine hydrochloride
US7470435B2 (en) 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
CA2476101A1 (en) * 2004-08-12 2006-02-12 Bernard Charles Sherman Extended-release capsules comprising venlafaxine hydrochloride
AU2006274565B2 (en) * 2005-08-02 2012-05-17 Lupin Limited Novel controlled release compositions of selective serotonin reuptake inhibitors
JP2008231025A (ja) * 2007-03-20 2008-10-02 Kyowa Yakuhin Kogyo Kk マレイン酸フルボキサミン錠剤
WO2018206923A1 (en) * 2017-05-11 2018-11-15 Opal Ip Limited Novel formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2077023T3 (es) * 1989-03-10 1995-11-16 Yamanouchi Pharma Co Ltd Material de recubrimiento que controla la liberacion de un medicamento para formulaciones de actividad prolongada.
JPH04234812A (ja) * 1990-03-16 1992-08-24 Yamanouchi Pharmaceut Co Ltd 持続性製剤用顆粒
JPH0826977A (ja) * 1994-07-19 1996-01-30 Tanabe Seiyaku Co Ltd 溶出制御型経口製剤
JP4072597B2 (ja) * 1994-12-27 2008-04-09 ナムローゼ・フェンノートシャップ・オルガノン 持続性製剤
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
FR2754710B1 (fr) * 1996-10-22 1998-12-31 Prographarm Lab Procede de preparation d'une forme pharmaceutique multiparticulaire a liberation controlee plurisequentielle
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
WO1999001121A1 (en) * 1997-07-01 1999-01-14 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
BR9809895A (pt) * 1997-07-01 2000-08-01 Pfizer Prod Inc Formas de dosagem da sertralina de liberação retardada
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation

Also Published As

Publication number Publication date
CA2698347A1 (en) 2000-11-30
CA2374039C (en) 2011-01-11
SK286865B6 (sk) 2009-06-05
JP2003500348A (ja) 2003-01-07
EP1178780B1 (en) 2007-07-18
HUP0201884A3 (en) 2006-07-28
ATE367153T1 (de) 2007-08-15
AU4426700A (en) 2000-12-12
SK18962001A3 (sk) 2002-04-04
EP1178780A1 (en) 2002-02-13
DE60035579D1 (de) 2007-08-30
CZ302388B6 (cs) 2011-04-27
DZ3256A1 (fr) 2000-11-30
CA2374039A1 (en) 2000-11-30
EP1852111A1 (en) 2007-11-07
CY1107750T1 (el) 2013-04-18
ES2290027T3 (es) 2008-02-16
RU2275191C2 (ru) 2006-04-27
HU229569B1 (hu) 2014-02-28
PT1178780E (pt) 2007-10-25
HUP0201884A2 (en) 2002-09-28
AU782059B2 (en) 2005-06-30
DE60035579T2 (de) 2008-04-17
WO2000071099A1 (en) 2000-11-30
CZ20014618A3 (cs) 2002-05-15

Similar Documents

Publication Publication Date Title
DE60121857D1 (de) Arzneimittelzusammensetzung mit verzögerter Wirkstoffabgabe
CY1107750T1 (el) Πολυσωματιδιακα σκευασματα ελεγχομενης αποδεσμευσης εκλεκτικου αναστολεα επαναπροσληψης σεροτονινης
RS50924B (sr) Oralni dozni oblici propiverina ili njegovih farmaceutski prihvatljivih soli sa produženim oslobađanjem aktivne materije
EP2266542A3 (en) Controlled release nanoparticulate compositions
DK0939626T3 (da) Galenisk form til forlænget frigivelse af milnacipran
DE69622510D1 (de) Nifedipinzubereitung mit langanhaltender Freisetzung
DK1213015T3 (da) Oralt farmaceutisk præparat med forsinket frigivelse af protonpumpeinhibitorer
NZ314442A (en) Extended release formulation comprising venlafaxine hydrochloride, film coating composition
CA2355644A1 (en) Controlled/modified release oral methylphenidate formulations
MY148475A (en) Controlled release preparations comprising tramadol and topiramate
EA200001201A3 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
TR200102811T2 (tr) Oral uygulama için, tolpersiyon içeren farmasötik preparat.
DE60042168D1 (de) Chronotherapeutische diltiazem formulierungen und deren verabreichung
AP2001002233A0 (en) Particulate composition of eletriptan
CA2415154A1 (en) Modified release formulations of selective serotonin re-uptake inhibitors
NO982904D0 (no) Oral farmas°ytisk sammensetning inneholdende 5-ASA, med modifisert frigj°ring, og fremgangsmÕte for behandling av tarmsykdommer
EP1254668A3 (en) Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression
UA74335C2 (uk) Мультичастинкова композиція контрольованого вивільнення флувоксаміну та спосіб лікування станів, які лікуються за допомогою селективних інгібіторів зворотного захоплення серотоніну
BRPI9916820B8 (pt) composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método
BR0114395A (pt) Composição farmacêutica para administração por suprimento via oral
SG145717A1 (en) Composition for releasing a weak base for an extended period of time
HRP20000704B1 (en) Controlled release peroral compositions of levosimendan
AU3763495A (en) Enteric coated compositions of 1,5-benzodiazepine derivatives having cck antagonistic or agonistic activity
TH43680A (th) เกลือเชอร์ทราลีนและรูปแบบการใช้ที่มีการหน่วงการปลดปล่อยของเซอร์ทราลีน